Bryostatin 1 - Neurotrope BioScience

Drug Profile

Bryostatin 1 - Neurotrope BioScience

Alternative Names: Bryostatin-1 - Neurotrope

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience
  • Developer Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience; Rettsyndrome.org
  • Class Antineoplastics; Macrocyclic compounds
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Fragile X syndrome; Niemann-Pick disease type C; Rett syndrome

Most Recent Events

  • 22 Aug 2017 Chemical structure information added
  • 19 Jul 2017 Neurotrope Bioscience completes a phase IIb trial in Alzheimer's disease in USA (IV) (NCT02431468)
  • 19 Jul 2017 Updated efficacy data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top